However, further analyses in a larger AML series are needed to confirm that expression analysis of a set of just six genes could help refine the risk stratification of patients who achieve complete remission in response to standard induction therapy and to establish which patients are likely to benefit from therapy with BCL2 and/or BRD4 inhibitors. Here, BCL2 is linked to acute myeloid leukemia.